Cited 0 times in
Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 천재희 | - |
dc.date.accessioned | 2021-09-29T02:23:46Z | - |
dc.date.available | 2021-09-29T02:23:46Z | - |
dc.date.issued | 2021-09 | - |
dc.identifier.issn | 2040-6223 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184866 | - |
dc.description.abstract | Background: A large proportion of patients with inflammatory bowel disease (IBD) relapse after drug discontinuation despite achieving a stable state of infliximab-induced clinical remission. Resuming the use of the same tumor necrosis factor-alpha (TNF-α) inhibitors in patients who relapse following TNF-α inhibitor discontinuation was suggested as a treatment strategy. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of infliximab retreatment in patients with IBD. Methods: A systematic literature search to shortlist relevant studies was conducted using the MEDLINE, Embase, CINAHL, and SCOPUS databases for studies published from inception to August 2020. Results: Nine studies were included in the meta-analysis. The pooled clinical remission rate of infliximab retreatment in patients with IBD was 85% (95% confidence interval (CI), 81–89%) for induction treatment and 73% (95% CI, 66–80%) for maintenance treatment. A clinical remission rate following infliximab reintroduction was achieved in a greater proportion of patients with Crohn’s disease (87%; 95% CI, 83–91%) than in those with ulcerative colitis (78%; 95% CI, 61–91%) for induction treatment, but the difference was not statistically significant. Infusion-related reactions after infliximab retreatment occurred in 9% of patients with IBD (95% CI, 3–16%). Conclusion: Infliximab retreatment showed high clinical remission rates with tolerable infusion-related reactions in patients with IBD who achieved remission with initial infliximab treatment but relapsed after its discontinuation. We suggest infliximab as a viable alternative in patients with IBD who previously responded well to infliximab treatment. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | SAGE Publications | - |
dc.relation.isPartOf | THERAPEUTIC ADVANCES IN CHRONIC DISEASE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Seungwon Yang | - |
dc.contributor.googleauthor | Siyoung Yang | - |
dc.contributor.googleauthor | Young Kwon Jo | - |
dc.contributor.googleauthor | Seungyeon Kim | - |
dc.contributor.googleauthor | Min Jung Chang | - |
dc.contributor.googleauthor | Junjeong Choi | - |
dc.contributor.googleauthor | Jae Hee Cheon and Yun Mi Yu | - |
dc.contributor.localId | A04030 | - |
dc.relation.journalcode | J04111 | - |
dc.identifier.eissn | 2040-6231 | - |
dc.subject.keyword | clinical remission | - |
dc.subject.keyword | inflammatory bowel disease | - |
dc.subject.keyword | infliximab | - |
dc.subject.keyword | infusion-related reaction | - |
dc.subject.keyword | retreatment | - |
dc.contributor.alternativeName | Cheon, Jae Hee | - |
dc.contributor.affiliatedAuthor | 천재희 | - |
dc.citation.volume | 12 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 12 | - |
dc.identifier.bibliographicCitation | THERAPEUTIC ADVANCES IN CHRONIC DISEASE, Vol.12 : 1-12, 2021-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.